Morgan Stanley analyst David Risinger attributes Friday's 3% decline in Bausch Health (BHC)shares to concerns that the company is exposed to liabilities related to the talc powder lawsuits being faced by Johnson & Johnson (JNJ) since Bausch acquired right to Shower to Shower talc powder in 2012. However, he believes the negative reaction is likely overblown since Bausch appears to be indemnified by J&J, has been successful in obtaining dismissals of related cases, and has only owned the product rights for the past six year. Risinger maintains an Overweight rating and $32 price target on Bausch Health shares.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here